All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During ASCO 2019, Chicago, US, Alison J Moskowitz, Memorial Sloan Kettering Cancer Center, New York, US, spoke to the Lymphoma Hub about pre-transplant salvage options: bringing conventional versus novel combinations to practice.
Dr. Moskowitz explains that the general approach for a patient that has relapsed or refactor disease after their frontline treatment for Hodgkin lymphoma (HL) is to give some kind of second-line therapy followed by consolidation with an autologous stem cell transplant and the choice of treatment is dependant upon the institution treating the patient. These treatments may include traditional therapies such as ICE, chemotherapy, or DHAP based regimes. However, now that there are newer regimes available for HL such as rituximab and checkpoint inhibitors these are now being considered when treating second-line therapy patients.
Pre-transplant salvage options: bringing conventional versus novel combinations to practice
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox